Cancer Biomarkers Market - By Type: Protein Biomarkers, Genetic Biomarkers, Metabolic Biomarkers; By Application: Diagnostics, Prognostics, Drug Discovery & Development; By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others; By End-User: Hospitals, Research Laboratories, Diagnostic Centers; By Region: North America, Europe, Asia-Pacific, Latin America, Middle East & Africa.
The global cancer biomarkers market was valued at USD 18.6 billion in 2023 and is projected to reach USD 48.3 billion by 2031, growing at a 12.7% CAGR (ClearView Market Insights, 2024). The adoption of precision oncology, advancements in liquid biopsy, and AI-driven diagnostic platforms fuel this expansion.
2. Technological Breakthroughs (2024)
2.1 Liquid Biopsy Innovations
2.2 AI/ML Integration
|
Platform |
Function |
Clinical Impact |
|
Paige Prostate |
AI pathology (99% sensitivity) |
Reduces false negatives by 45% |
|
Tempus xF |
Genomic + clinical data fusion |
30% faster therapy matching |
|
PathAI’s PD-L1 |
Automated scoring |
Cuts interpretation time by 70% |
2.3 Novel Biomarker Classes
3. Application-Specific Advances
3.1 Solid Tumors (XX% Market Share)
3.2 Hematologic Malignancies (XX%)
3.3 Early Detection (XX%)
4. Competitive Landscape
|
Company |
Market Share |
Flagship Product |
2024 Launch |
|
Roche |
24% |
FoundationOne® Liquid |
TMB/MSI + HRD scoring |
|
Guardant Health |
19% |
Guardant360® CDx |
1,000+ mutation panel |
|
Exact Sciences |
15% |
Cologuard® |
Multi-cancer RNA signatures |
|
Natera |
12% |
Signatera™ |
ctDNA recurrence monitoring |
Emerging Players:
5. Regional Adoption
Need help?
Chat with our team in a minute.